Skip to content
value.today

Sight Sciences, Inc.: peers

Change the peers

Sight Sciences, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Sight Sciences, Inc., NeuroPace, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Sight Sciences, Inc., NeuroPace, Inc., Delcath Systems, Inc., 908 Devices Inc., Orthofix Medical Inc., CapsoVision, Inc., Tactile Systems Technology, Inc., OrthoPediatrics Corp. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureSight Sciences, Inc.base
SGHT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
NeuroPace, Inc.
NPCE · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Delcath Systems, Inc.
DCTH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
908 Devices Inc.
MASS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Orthofix Medical Inc.
OFIX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CapsoVision, Inc.
CV · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Tactile Systems Technology, Inc.
TCMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
OrthoPediatrics Corp.
KIDS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$448 MAug 1, 2026 · Market data6th of 8$487 MSep 18, 2026 · Market data5th of 8$500 MOct 20, 2026 · Market data4th of 8$503 MOct 14, 2026 · Market data3rd of 8$377 MOct 15, 2026 · Market data7th of 8$372 MOct 30, 2026 · Market data8th of 8$545 MOct 30, 2026 · Market data2nd of 8$573 MOct 19, 2026 · Market data1st of 8$494 M8 ranked
Revenue (Better neither way: ranked highest first)$77 MFY2025 · SEC6th of 8$100 MFY2025 · SEC4th of 8$85 MFY2025 · SEC5th of 8$56 MFY2025 · SEC7th of 8$822 MFY2025 · SEC1st of 8$14 MFY2025 · SEC8th of 8$330 MFY2025 · SEC2nd of 8$236 MFY2025 · SEC3rd of 8$93 M8 ranked
Net income (Higher is better)$-38 MFY2025 · SEC6th of 8$-21 MFY2025 · SEC4th of 8$3 MFY2025 · SEC3rd of 8$19 MFY2025 · SEC1st of 8$-92 MFY2025 · SEC8th of 8$-25 MFY2025 · SEC5th of 8$19 MFY2025 · SEC2nd of 8$-40 MFY2025 · SEC7th of 8$-23 M8 ranked
Employees (Better neither way: ranked highest first)186December 31, 2025 · Profile4th of 7209December 31, 2025 · Profile2nd of 7156February 13, 2026 · Profile5th of 796As on September 2020 · Profile7th of 7——99December 31, 2025 · Profile6th of 7988As on 2021 · Profile1st of 7203As on 2022 · Profile3rd of 71867 ranked
Growth
Revenue growth (Higher is better)-3.1%FY2025 · SEC8th of 820th21st+25.1%FY2025 · SEC2nd of 873rd83rd+129.1%FY2025 · SEC1st of 894th97th+17.7%FY2025 · SEC3rd of 864th75th+2.9%FY2025 · SEC7th of 832nd38th+15.2%FY2025 · SEC5th of 859th71st+12.5%FY2025 · SEC6th of 855th67th+15.4%FY2025 · SEC4th of 860th72nd+15.3%8 ranked
Revenue growth, 3 years a year (Higher is better)+2.7%FY2025 · SEC7th of 735th43rd+30.0%FY2025 · SEC2nd of 781st91st+215.3%FY2025 · SEC1st of 799th100th+6.3%FY2025 · SEC6th of 746th57th+21.3%FY2025 · SEC4th of 773rd86th————+10.1%FY2025 · SEC5th of 753rd70th+24.6%FY2025 · SEC3rd of 777th88th+21.3%7 ranked
Earnings per share growth (Higher is better)————————————————————————+17.1%FY2025 · SEConly one with it60th60th————+17.1%—
Margins and returns
Gross margin (Higher is better)86.2%FY2025 · SEC1st of 887th95th77.2%FY2025 · SEC3rd of 878th89th86.2%FY2025 · SEC2nd of 887th95th50.6%FY2025 · SEC8th of 837th64th68.8%FY2025 · SEC6th of 866th81st52.9%FY2025 · SEC7th of 840th66th75.9%FY2025 · SEC4th of 876th88th73.0%FY2025 · SEC5th of 871st85th74.5%8 ranked
Operating margin (Higher is better)-48.0%FY2025 · SEC6th of 832nd15th-16.3%FY2025 · SEC4th of 843rd23rd0.8%FY2025 · SEC2nd of 859th42nd-70.1%FY2025 · SEC7th of 827th13th-9.9%FY2025 · SEC3rd of 849th28th-188.3%FY2025 · SEC8th of 816th6th8.9%FY2025 · SEC1st of 871st65th-16.6%FY2025 · SEC5th of 843rd23rd-16.5%8 ranked
Net margin (Higher is better)-49.7%FY2025 · SEC7th of 832nd15th-21.5%FY2025 · SEC6th of 842nd21st3.2%FY2025 · SEC3rd of 867th55th34.7%FY2025 · SEC1st of 896th96th-11.2%FY2025 · SEC4th of 847th26th-186.9%FY2025 · SEC8th of 816th7th5.8%FY2025 · SEC2nd of 871st64th-16.8%FY2025 · SEC5th of 844th23rd-14.0%8 ranked
Free cash flow margin (Higher is better)-38.7%FY2025 · SEC6th of 830th13th-11.3%FY2025 · SEC5th of 842nd21st24.6%FY2025 · SEC1st of 893rd93rd-43.9%FY2025 · SEC7th of 828th13th-0.2%FY2025 · SEC3rd of 852nd34th-169.4%FY2025 · SEC8th of 817th5th12.3%FY2025 · SEC2nd of 875th75th-6.8%FY2025 · SEC4th of 844th24th-9.0%8 ranked
Return on equity (Higher is better)-50.8%FY2025 · SEC6th of 743rd18th-158.7%FY2025 · SEC7th of 715th7th3.0%FY2025 · SEC3rd of 775th47th15.1%FY2025 · SEC1st of 787th78th-19.3%FY2025 · SEC5th of 760th28th————8.8%FY2025 · SEC2nd of 780th61st-11.3%FY2025 · SEC4th of 766th32nd-11.3%7 ranked
Return on invested capital (Higher is better)————————————————————————13.2%FY2025 · SEConly one with it56th59th————13.2%—
Valuation
P/E ratio (Better neither way: ranked highest first)————————75.2×price Oct 20, 2026 · Market data1st of 283rd92nd————————————22.9×price Oct 30, 2026 · Market data2nd of 238th60th————49.0×2 ranked
Price to sales (Better neither way: ranked highest first)5.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price4.8×price Sep 18, 2026 · Market datanot ranked: old priceold priceold price4.5×price Oct 20, 2026 · Market data3rd of 655th74th7.6×price Oct 14, 2026 · Market data2nd of 667th85th0.5×price Oct 15, 2026 · Market data6th of 67th14th26.8×price Oct 30, 2026 · Market data1st of 687th95th1.5×price Oct 30, 2026 · Market data5th of 625th40th2.2×price Oct 19, 2026 · Market data4th of 636th51st3.4×6 ranked
Price to book (Better neither way: ranked highest first)7.0×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price25.6×price Sep 18, 2026 · Market datanot ranked: old priceold priceold price4.5×price Oct 20, 2026 · Market data2nd of 664th74th3.5×price Oct 14, 2026 · Market data3rd of 656th67th0.8×price Oct 15, 2026 · Market data6th of 616th16th28.1×price Oct 30, 2026 · Market data1st of 695th97th2.5×price Oct 30, 2026 · Market data4th of 643rd56th1.6×price Oct 19, 2026 · Market data5th of 634th40th3.0×6 ranked
Free cash flow yield (Higher is better)-6.7%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-2.3%price Sep 18, 2026 · Market datanot ranked: old priceold priceold price4.2%price Oct 20, 2026 · Market data2nd of 684th61st-4.9%price Oct 14, 2026 · Market data5th of 655th27th-0.3%price Oct 15, 2026 · Market data3rd of 667th36th-6.2%price Oct 30, 2026 · Market data6th of 651st25th7.4%price Oct 30, 2026 · Market data1st of 692nd78th-2.8%price Oct 19, 2026 · Market data4th of 660th30th-1.6%6 ranked
Financial strength
Debt to equity (Lower is better)0.7×FY2025 · SEC4th of 562nd53rd3.1×FY2025 · SEC5th of 592nd91st————————0.3×FY2025 · SEC3rd of 543rd34th————0.0×FY2025 · SEC1st of 54th3rd0.3×FY2025 · SEC2nd of 539th31st0.3×5 ranked
Net debt to EBITDA (Lower is better)————————————————————————-2.3×FY2025 · SEConly one with it7th4th————-2.3×—
Interest cover (Higher is better)-7.2×FY2025 · SEConly one with it49th26th————————————————————————————-7.2×—
Piotroski F-score (Higher is better)5 of 9FY2025 · SEC1st of 45 of 9FY2025 · SEC1st of 4————5 of 9FY2025 · SEC1st of 4————4 of 9FY2025 · SEC4th of 45.0 of 94 ranked
Scorecard
Scorecard (Higher is better)4 of 18FY2025 · Scorecard8th of 87 of 18FY2025 · Scorecard5th of 811 of 21FY2025 · Scorecard2nd of 810 of 20FY2025 · Scorecard4th of 88 of 21FY2025 · Scorecard6th of 83 of 11FY2025 · Scorecard7th of 821 of 26FY2025 · Scorecard1st of 811 of 21FY2025 · Scorecard2nd of 844% passed8 ranked
Valuation checks (Higher is better)————0 of 5FY2025 · Scorecard4th of 60 of 5FY2025 · Scorecard4th of 62 of 5FY2025 · Scorecard2nd of 60 of 5FY2025 · Scorecard4th of 64 of 6FY2025 · Scorecard1st of 62 of 5FY2025 · Scorecard2nd of 620% passed6 ranked
Growth checks (Higher is better)0 of 6FY2025 · Scorecard8th of 85 of 6FY2025 · Scorecard2nd of 85 of 5FY2025 · Scorecard1st of 85 of 6FY2025 · Scorecard2nd of 84 of 6FY2025 · Scorecard5th of 81 of 2FY2025 · Scorecard7th of 85 of 6FY2025 · Scorecard2nd of 84 of 6FY2025 · Scorecard5th of 875% passed8 ranked
Profitability checks (Higher is better)1 of 5FY2025 · Scorecard4th of 81 of 5FY2025 · Scorecard4th of 83 of 5FY2025 · Scorecard2nd of 83 of 5FY2025 · Scorecard2nd of 80 of 5FY2025 · Scorecard7th of 80 of 2FY2025 · Scorecard7th of 84 of 6FY2025 · Scorecard1st of 81 of 5FY2025 · Scorecard4th of 820% passed8 ranked
Financial health checks (Higher is better)3 of 6FY2025 · Scorecard6th of 81 of 4FY2025 · Scorecard8th of 82 of 3FY2025 · Scorecard4th of 82 of 3FY2025 · Scorecard4th of 82 of 4FY2025 · Scorecard6th of 82 of 2FY2025 · Scorecard1st of 85 of 5FY2025 · Scorecard1st of 83 of 4FY2025 · Scorecard3rd of 867% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard4th of 70 of 3FY2025 · Scorecard4th of 71 of 3FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard4th of 70 of 1FY2025 · Scorecard4th of 7——3 of 3FY2025 · Scorecard1st of 71 of 1FY2025 · Scorecard1st of 70% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)41.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 877.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 859.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 888.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 896.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 811.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8101.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 866.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 871.9%8 ranked
Institutions holding (Better neither way: ranked highest first)1312026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 81052026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 81452026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 81232026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 81362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8502026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 81622026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 81412026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 81348 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)-1.1 pp2026-Q2 against 2026-Q1 · 13F6th of 8-1.2 pp2026-Q2 against 2026-Q1 · 13F7th of 8+2.9 pp2026-Q2 against 2026-Q1 · 13F2nd of 8-4.6 pp2026-Q2 against 2026-Q1 · 13F8th of 8+4.9 pp2026-Q2 against 2026-Q1 · 13F1st of 8+2.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 8+1.4 pp2026-Q2 against 2026-Q1 · 13F4th of 8+0.8 pp2026-Q2 against 2026-Q1 · 13F5th of 8+1.1 pp8 ranked
Dividends
Shareholder yield (Higher is better)————10.2%FY2025 · SECnot ranked: old priceold priceold price1.2%FY2025 · SEC2nd of 235th24th————————————4.9%FY2025 · SEC1st of 276th67th————3.0%2 ranked
Dividend per share (Better neither way: ranked highest first)——$0.00FY2025 · SEConly one with it————————————$0.00—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Sight Sciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NeuroPace, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Delcath Systems, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; 908 Devices Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Orthofix Medical Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CapsoVision, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tactile Systems Technology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; OrthoPediatrics Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Sight Sciences, Inc.-48.0%FY2025
32nd percentile in Healthcaremedian -7.8%, 678 companies
15th percentile in USAmedian 3.4%, 2,607 companies
NeuroPace, Inc.-16.3%FY2025
43rd percentile in Healthcaremedian -7.8%, 678 companies
23rd percentile in USAmedian 3.4%, 2,607 companies
Delcath Systems, Inc.0.8%FY2025
59th percentile in Healthcaremedian -7.8%, 678 companies
42nd percentile in USAmedian 3.4%, 2,607 companies
908 Devices Inc.-70.1%FY2025
27th percentile in Healthcaremedian -7.8%, 678 companies
13th percentile in USAmedian 3.4%, 2,607 companies
Orthofix Medical Inc.-9.9%FY2025
49th percentile in Healthcaremedian -7.8%, 678 companies
28th percentile in USAmedian 3.4%, 2,607 companies
CapsoVision, Inc.-188.3%FY2025
16th percentile in Healthcaremedian -7.8%, 678 companies
6th percentile in USAmedian 3.4%, 2,607 companies
Tactile Systems Technology, Inc.8.9%FY2025
71st percentile in Healthcaremedian -7.8%, 678 companies
65th percentile in USAmedian 3.4%, 2,607 companies
OrthoPediatrics Corp.-16.6%FY2025
43rd percentile in Healthcaremedian -7.8%, 678 companies
23rd percentile in USAmedian 3.4%, 2,607 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$206 M$411 M$617 M$822 M20102012201420162018202020222024Sight Sciences, Inc. $77 MNeuroPace, Inc. $100 MDelcath Systems, Inc. $85 M908 Devices Inc. $56 MOrthofix Medical Inc. $822 MCapsoVision, Inc. $14 MTactile Systems Technology, Inc. $330 MOrthoPediatrics Corp. $236 M

Rank in the group

1st2nd3rd4th5th6th7th8th20122013201420152016201720182019202020212022202320242025Sight Sciences, Inc.: 5th of 6 in 2020Sight Sciences, Inc.: 4th of 7 in 2021Sight Sciences, Inc.: 4th of 7 in 2022Sight Sciences, Inc.: 4th of 7 in 2023Sight Sciences, Inc.: 5th of 8 in 2024Sight Sciences, Inc.: 6th of 8 in 2025Sight Sciences, Inc.NeuroPace, Inc.: 4th of 6 in 2020NeuroPace, Inc.: 5th of 7 in 2021NeuroPace, Inc.: 6th of 7 in 2022NeuroPace, Inc.: 5th of 7 in 2023NeuroPace, Inc.: 4th of 8 in 2024NeuroPace, Inc.: 4th of 8 in 2025NeuroPace, Inc.Delcath Systems, Inc.: 2nd of 2 in 2012Delcath Systems, Inc.: 2nd of 2 in 2013Delcath Systems, Inc.: 3rd of 3 in 2014Delcath Systems, Inc.: 4th of 4 in 2015Delcath Systems, Inc.: 4th of 4 in 2016Delcath Systems, Inc.: 4th of 4 in 2017Delcath Systems, Inc.: 7th of 7 in 2021Delcath Systems, Inc.: 7th of 7 in 2022Delcath Systems, Inc.: 7th of 7 in 2023Delcath Systems, Inc.: 7th of 8 in 2024Delcath Systems, Inc.: 5th of 8 in 2025Delcath Systems, Inc.908 Devices Inc.: 6th of 6 in 2020908 Devices Inc.: 6th of 7 in 2021908 Devices Inc.: 5th of 7 in 2022908 Devices Inc.: 6th of 7 in 2023908 Devices Inc.: 6th of 8 in 2024908 Devices Inc.: 7th of 8 in 2025908 Devices Inc.Orthofix Medical Inc.: 1st of 2 in 2012Orthofix Medical Inc.: 1st of 2 in 2013Orthofix Medical Inc.: 1st of 3 in 2014Orthofix Medical Inc.: 1st of 4 in 2015Orthofix Medical Inc.: 1st of 4 in 2016Orthofix Medical Inc.: 1st of 4 in 2017Orthofix Medical Inc.: 1st of 3 in 2018Orthofix Medical Inc.: 1st of 3 in 2019Orthofix Medical Inc.: 1st of 6 in 2020Orthofix Medical Inc.: 1st of 7 in 2021Orthofix Medical Inc.: 1st of 7 in 2022Orthofix Medical Inc.: 1st of 7 in 2023Orthofix Medical Inc.: 1st of 8 in 2024Orthofix Medical Inc.: 1st of 8 in 2025Orthofix Medical Inc.CapsoVision, Inc.: 8th of 8 in 2024CapsoVision, Inc.: 8th of 8 in 2025CapsoVision, Inc.Tactile Systems Technology, Inc.: 2nd of 3 in 2014Tactile Systems Technology, Inc.: 2nd of 4 in 2015Tactile Systems Technology, Inc.: 2nd of 4 in 2016Tactile Systems Technology, Inc.: 2nd of 4 in 2017Tactile Systems Technology, Inc.: 2nd of 3 in 2018Tactile Systems Technology, Inc.: 2nd of 3 in 2019Tactile Systems Technology, Inc.: 2nd of 6 in 2020Tactile Systems Technology, Inc.: 2nd of 7 in 2021Tactile Systems Technology, Inc.: 2nd of 7 in 2022Tactile Systems Technology, Inc.: 2nd of 7 in 2023Tactile Systems Technology, Inc.: 2nd of 8 in 2024Tactile Systems Technology, Inc.: 2nd of 8 in 2025Tactile Systems TechnologyOrthoPediatrics Corp.: 3rd of 4 in 2015OrthoPediatrics Corp.: 3rd of 4 in 2016OrthoPediatrics Corp.: 3rd of 4 in 2017OrthoPediatrics Corp.: 3rd of 3 in 2018OrthoPediatrics Corp.: 3rd of 3 in 2019OrthoPediatrics Corp.: 3rd of 6 in 2020OrthoPediatrics Corp.: 3rd of 7 in 2021OrthoPediatrics Corp.: 3rd of 7 in 2022OrthoPediatrics Corp.: 3rd of 7 in 2023OrthoPediatrics Corp.: 3rd of 8 in 2024OrthoPediatrics Corp.: 3rd of 8 in 2025OrthoPediatrics Corp.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearSight Sciences, Inc.NeuroPace, Inc.Delcath Systems, Inc.908 Devices Inc.Orthofix Medical Inc.CapsoVision, Inc.Tactile Systems Technology, Inc.OrthoPediatrics Corp.
2025$77 MSEC6th$100 MSEC4th$85 MSEC5th$56 MSEC7th$822 MSEC1st$14 MSEC8th$330 MSEC2nd$236 MSEC3rd
2024$80 MSEC5th$80 MSEC4th$37 MSEC7th$48 MSEC6th$799 MSEC1st$12 MSEC8th$293 MSEC2nd$205 MSEC3rd
2023$81 MSEC4th$65 MSEC5th$2 MSEC7th$50 MSEC6th$747 MSEC1st—$274 MSEC2nd$149 MSEC3rd
2022$71 MSEC4th$46 MSEC6th$3 MSEC7th$47 MSEC5th$461 MSEC1st—$247 MSEC2nd$122 MSEC3rd
2021$49 MSEC4th$45 MSEC5th$4 MSEC7th$42 MSEC6th$464 MSEC1st—$208 MSEC2nd$98 MSEC3rd
2020$28 MSEC5th$41 MSEC4th—$27 MSEC6th$407 MSEC1st—$187 MSEC2nd$71 MSEC3rd
2019————$460 MSEC1st—$189 MSEC2nd$73 MSEC3rd
2018————$453 MSEC1st—$144 MSEC2nd$58 MSEC3rd
2017——$3 MSEC4th—$434 MSEC1st—$109 MSEC2nd$46 MSEC3rd
2016——$2 MSEC4th—$410 MSEC1st—$85 MSEC2nd$37 MSEC3rd
2015——$2 MSEC4th—$396 MSEC1st—$63 MSEC2nd$31 MSEC3rd
2014——$1 MSEC3rd—$402 MSEC1st—$48 MSEC2nd—

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Sight Sciences, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • NeuroPace, Inc.NPCE · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $487 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $487 M (Sep 18, 2026) · revenue $100 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Delcath Systems, Inc.DCTH · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $500 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $500 M (Oct 20, 2026) · revenue $85 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • 908 Devices Inc.MASS · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $503 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $503 M (Oct 14, 2026) · revenue $56 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Orthofix Medical Inc.OFIX · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $377 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $377 M (Oct 15, 2026) · revenue $822 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • CapsoVision, Inc.CV · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $372 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $372 M (Oct 30, 2026) · revenue $14 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Tactile Systems Technology, Inc.TCMD · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $545 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $545 M (Oct 30, 2026) · revenue $330 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • OrthoPediatrics Corp.KIDS · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $573 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $573 M (Oct 19, 2026) · revenue $236 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • ClearPoint Neuro, Inc.CLPT · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $296 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $297 M (Oct 22, 2026) · revenue $37 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • MiMedx Group, Inc.MDXG · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $684 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $684 M (Oct 14, 2026) · revenue $419 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Treace Medical Concepts, Inc.TMCI · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $280 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $280 M (Oct 26, 2026) · revenue $213 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Artivion, Inc.AORT · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $739 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $739 M (Oct 30, 2026) · revenue $441 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Cytek Biosciences, Inc.CTKB · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $770 M market cap against $448 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $770 M (Oct 27, 2026) · revenue $201 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.